



Depósito de Investigación  
Universidad de Sevilla

Depósito de investigación de la Universidad de Sevilla

<https://idus.us.es/>

“This is an Accepted Manuscript of an article published by Elsevier in:  
TALANTA on 2014, available at: <https://doi.org/10.1016/j.talanta.2013.12.016>”

1       **Design and implementation of an automated liquid-phase**  
2       **microextraction-chip system coupled on-line with high**  
3       **performance liquid chromatography**

4  
5       Bin Li<sup>a</sup>, Nickolaj Jacob Petersen<sup>a,\*</sup>, María D. Ramos Payán<sup>b</sup>, Steen Honoré Hansen<sup>a</sup>, and Stig  
6       Pedersen-Bjergaard<sup>a,c</sup>

7       <sup>a</sup> Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen,  
8       2100 Copenhagen, Denmark

9       <sup>b</sup> Department of Analytical Chemistry, Faculty of Chemistry, University of Seville, P.O. Box  
10       41012, Seville, Spain

11       <sup>c</sup> School of Pharmacy, University of Oslo, P.O Box 1068 Blindern, 0316 Oslo, Norway

12  
13  
14  
15       **Keywords:** Automated liquid-phase microextraction  
16                    On-line sample pretreatment  
17                    Microfluidic chip  
18                    High performance liquid chromatography  
19                    Opium alkaloids

20  
21       \*Corresponding author at: Department of Pharmacy, Faculty of Health and Medical Sciences,  
22       University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark, Tel.: +45  
23       35336184; E-mail address: [nickolaj.petersen@sund.ku.dk](mailto:nickolaj.petersen@sund.ku.dk)

25 **Abstract**

26 An automated liquid-phase microextraction (LPME) device in a chip format has been developed  
27 and coupled directly to high performance liquid chromatography (HPLC). A 10-port 2-position  
28 switching valve was used to hyphenate the LPME-chip with the HPLC autosampler, and to  
29 collect the extracted analytes, which then were delivered to the HPLC column. The LPME-chip-  
30 HPLC system was completely automated and controlled by the software of the HPLC instrument.  
31 The performance of this system was demonstrated with five alkaloids i.e. morphine, codeine,  
32 thebaine, papaverine, and noscapine as model analytes. The composition of the supported liquid  
33 membrane (SLM) and carrier was optimized in order to achieve reasonable extraction  
34 performance of all the five alkaloids. With 1-octanol as SLM solvent and with 25 mM sodium  
35 octanoate as anionic carrier, extraction recoveries for the different opium alkaloids ranged  
36 between 17 and 45 %. The extraction provided high selectivity, and no interfering peaks in the  
37 chromatograms were observed when applied to human urine samples spiked with alkaloids. The  
38 detection limits using UV-detection were in the range of 1-21 ng/mL for the five opium alkaloids  
39 presented in water samples. The repeatability was within 5.0-10.8 % (RSD). The membrane  
40 liquid in the LPME-chip was regenerated automatically between every third injection. With this  
41 procedure the liquid membrane in the LPME-chip was stable in 3-7 days depending on the  
42 complexity of sample solutions with continuous operation. With this LPME-chip-HPLC system,  
43 series of samples were automatically injected, extracted, separated, and detected without any  
44 operator interaction.

45

46

## 47 **1. Introduction**

48 The high complexity of biological samples and low concentrations of target analytes are two  
49 of the main challenges for analytical detection and quantitation. Therefore, clean-up and  
50 enrichment procedures in order to resolve those analytical limitations are important, preferably in  
51 an automated way that is able to handle low sample volumes. For many years, liquid-liquid  
52 extraction (LLE), solid phase extraction (SPE), and solid-phase microextraction (SPME) have  
53 been the standard methods for sample preparation [1, 2]. In recent years, substantial interest has  
54 also been devoted to extractions across supported liquid membranes (SLM) where an organic  
55 liquid is immobilized in the pores of a porous hydrophobic membrane. Analytes of interest can be  
56 selectively extracted across the SLM driven by either a pH gradient as used in the format of  
57 liquid-phase microextraction (LPME) [3-6] or a voltage gradient termed electromembrane  
58 extraction (EME) [7]. With LPME or EME, membrane microextraction has demonstrated a  
59 significant potential in pharmaceutical analysis [8], environmental [9-11] and food analysis [12].

60 Due to the high versatility of SLM based extraction techniques, they are readily incorporated  
61 into different platforms and coupled directly with high performance analytical instruments such  
62 as liquid chromatography (LC) [13], gas chromatography (GC) [14], capillary electrophoresis  
63 (CE) [15], or flame atomic absorption spectrometry (AAS) [16]. Chip-based SLM- systems have  
64 been explored and coupled on-line with LC since the 1980s [17] due to their significant  
65 advantages in terms of miniaturization and automation [18]. Previous SLM-chip modules were  
66 made by packing a flat sheet membrane in between two grooved polymer holders, which were  
67 then clamped with bolts. The volume of the channels was generally in the range of 10-20  $\mu\text{L}$  [19,  
68 20]. The automated SLM-chip systems have been explored and applied for a wide range of  
69 biosamples, such as anaesthetics (SLM-GC) [21], bambuterol in human plasma (SLM-CE) [22],  
70 and peptides in spiked plasma (SLM-HPLC) [19].

71 Recently, SLM extraction has been successfully downscaled to a microfluidic chip for sample  
72 enrichment and clean-up [23-26]. The advantages of such microchip membrane extraction  
73 include minimal organic solvent consumption, the ability to handle a wide range of sample  
74 volumes, ease of use, potentially high enrichment factors from small sample volumes, and the  
75 ability to provide selective extraction of analytes depending on their polarity and charge. The  
76 chemical binding of flat sheet membranes into polymethyl methacrylate (PMMA) blocks was

77 developed in our group and high performance of this SLM-chip unit has been demonstrated by  
78 both EME [24, 25, 27] and LPME [23] work reported previously. In this microchip membrane  
79 extraction module, the sample solution was pumped into a 50  $\mu\text{m}$  deep micro channel where the  
80 analytes were extracted through the SLM and into an acceptor channel located on the other side  
81 of the SLM. The driving force for the microchip membrane extraction was either a DC electrical  
82 potential [25], or a pH gradient [23]. With microchip membrane extraction, dynamic extraction  
83 was performed in which the samples were delivered continuously to the chip by a microsyringe  
84 pump. The enrichment factor (EF) was controlled by the ratio of the sample volume delivered to  
85 the device and the volume of the acceptor solution that could either be stationary (stopped flow)  
86 or delivered continuously [23, 24]. In addition, in the microchip EME system, the EF was also  
87 controlled by the applied extraction voltage [24]. Both the microchip EME and LPME systems  
88 have been used for online and real-time measurement of *in vitro* metabolism of drug substances  
89 by rat liver microsomes [23, 27].

90 The objective of this study was to integrate a microchip LPME system directly to a  
91 commercial high performance liquid chromatography (HPLC) system, and to fully automate the  
92 system. This report describes the design, construction, operation, and optimization of such a  
93 LPME-chip-HPLC system. The system was developed to automatically perform sample injection,  
94 LPME, SLM liquid regeneration, and fast HPLC separation. Different alkaloids were used as  
95 model analytes. The intention was not to develop an analytical method for the alkaloids, but  
96 rather to investigate fundamental aspects of the LPME-chip-HPLC system.

97

## 98 **2. Experimental**

### 99 **2.1 Chemicals and sample solutions**

100 Morphine ( $\text{pK}_a$  (base) = 8.2,  $\text{pK}_a$  (acid) = 9.7;  $\log P$  = 0.89) was obtained from Nycomed  
101 DAK (Copenhagen, Denmark), codeine ( $\text{pK}_a$  = 8.2;  $\log P$  = 1.19) and noscapine ( $\text{pK}_a$  = 6.3;  $\log P$   
102 = 1.5) were obtained from Nordisk Droge and Kemikalie (Copenhagen, Denmark), thebaine ( $\text{pK}_a$   
103 = 8.4;  $\log P$  = 2.0) was obtained from Nomeco (Copenhagen, Denmark), and papaverine ( $\text{pK}_a$  =  
104 6.3;  $\log P$  = 3.0) was obtained from Mecobenzon (Copenhagen, Denmark). All these substances  
105 were hydrochlorides and with purities >99 %. LC-MS grade formic acid, acetonitrile,  
106 tricaprilmethyl-ammonium chloride (Aliquat 336), and sodium octanoate were purchased from  
107 Sigma–Aldrich (St. Louis, MO, USA). 1-Octanol and 2-nitrophenyl octyl ether (NPOE) were

108 obtained from Fluka (Buchs, Switzerland). All water used was prepared with a Millipore Direct-  
109 Q3 UV system (Billerica, MA, USA).

110 Stock solutions containing 1 mg/mL of each model analyte were prepared in 10 % (v/v)  
111 acetonitrile in 100 mM HCOOH and stored protected from light at 277 K (4°C). Sample solutions  
112 of the compounds were prepared daily by adequate dilutions from the 1 mg/mL stock solutions  
113 by pure water or urine.

114

## 115 **2.2 Instrumentation of the automated LPME-chip-HPLC**

116 As show in Figure 1A, the integrated LPME-chip-HPLC consisted of three main parts: (1) an  
117 Agilent 1100 HPLC system (Agilent, Palo Alto, CA, USA) including an autosampler (model  
118 G1329A), a binary pump system (G1312A), and a UV detector (G1314A); (2) the home-built  
119 LPME-chip attached to a Valco Instrument (EHAM model, Houston, TX, USA) two position 10-  
120 port valve actuator control module; and (3) two microsyringe pumps (Kd Scientific, Holliston,  
121 MA). The HPLC software (Chemstation B.04.02) was applied for programming the sample  
122 injection, separation, and UV detection. The 10-port valve was used to synchronize the sample  
123 pretreatment, and to separate the low pressure of LPME-chip module from the high pressure of  
124 HPLC system by switching the positions between sample loading and injection. The automated  
125 operation of this 10-port valve was controlled by the remote control output (RS232 plug) on the  
126 HPLC system. The valve switching flow diagram for the LPME-chip-HPLC system is  
127 schematically illustrated in Figure 1B. In this setup, the two switch positions A and B in the 10-  
128 port valve were alternatively changed for microchip LPME sample pretreatment and on-line  
129 HPLC analysis, respectively. The two microsyringe pumps were used to deliver the sample  
130 carrier buffer solution and the acceptor phase through the LPME-chip for the dynamic extraction,  
131 respectively.

132 The construction of the LPME-chip was published recently and only a short description is  
133 given here [23, 27]. The porous polypropylene membrane (Celgard 2500 micro porous membrane;  
134 Celgard, Charlotte, NC, USA) with a 25  $\mu\text{m}$  thickness (55% porosity, and 0.21  $\mu\text{m} \times 0.05 \mu\text{m}$   
135 pores) used for the SLM was placed between two polymethyl methacrylate (PMMA) (53 mm  $\times$   
136 53 mm  $\times$  2.1 mm) plates having 6 mm long channels with a depth of 50  $\mu\text{m}$  and a width of 2.00  
137 mm. The whole assembly was fixed by solvent-assisted bonding with ethanol and cured in a

138 343K (70°C) oven. At both ends of the channels, 1.6 mm I.D. holes were drilled through the plate  
139 to serve as inlet and outlet for the sample carrier liquid and the acceptor phase.

140 Prior to connection of the tubing to the chip, the supported liquid membrane was immobilized  
141 in the polypropylene membrane by filling approximately 0.2  $\mu\text{L}$  of organic solvent (1-octanol or  
142 NPOE) into one end of the extraction channel using a micropipette. The solvent immediately  
143 immobilized into the polypropylene membrane by capillary forces, and this process was visually  
144 inspected as the appearance of the membrane changed from white to transparent during  
145 immobilization of membrane liquid. Subsequently, the tubings for the donor and acceptor flow  
146 were connected to the LPME-chip.

147

### 148 **2.3 Procedure of carrier mediated LPME-chip-HPLC**

149 Sample was loaded in the autosampler tray of the HPLC instrument in 2 mL LC vials  
150 (Microlab, Aarhus, Denmark), and extractions were normally carried out according to the  
151 following procedure; sample solution was prepared by the mixture of 500  $\mu\text{L}$  analyte solution  
152 with 500  $\mu\text{L}$  50 mM sodium octanoate (ion-pair reagent) prepared in 25 mM pH 7.0 phosphate  
153 buffer. By means of the autosampler, 50  $\mu\text{L}$  sample solution was draw into the injection needle  
154 and then directed back to the HPLC needle seat connected with the HPLC 6-port valve (all part of  
155 the Agilent® autosampler) (Figure 1A). The microsyringe on the donor side was connected with  
156 the 6-port valve of the autosampler, and was filled with 25 mM phosphate buffer (pH 7.0) used as  
157 the sample carrier liquid. With a flow rate of 5  $\mu\text{L}/\text{min}$ , the sample plug was transferred to the  
158 LPME-chip and the analytes were extracted through the SLM. The tubings used for connecting  
159 the LPME-chip to the autosampler had a small dead volume in the order of 1  $\mu\text{L}$ , also on the  
160 acceptor side there was a small dead volume of approximately 0.5  $\mu\text{L}$  for transferring the extracts  
161 to the 5  $\mu\text{L}$  HPLC loop. The total extraction time was set for the requirement of total injected  
162 sample reached the chip, and also that the extract was transferred to the 5  $\mu\text{L}$  sample loop. The  
163 time delay due to the dead volume was taken into account. Therefore, the on-chip membrane  
164 microextraction of 50  $\mu\text{L}$  sample solution will take 15 minutes with a flow rate of 5  $\mu\text{L}/\text{min}$  on  
165 the donor side. During the 15 minutes extraction, the analytes extracted into the acceptor solution  
166 were continuously delivered to the 5  $\mu\text{L}$  sample loop by the continuous flow of acceptor phase  
167 (50 mM HCl), which was pumped with a second microsyringe pump on the acceptor side at a  
168 flow rate of 0.5  $\mu\text{L}/\text{min}$ .

169 Analysis of the extracts, collected by the loop, was performed by switching the 10-port valve  
170 to position B after 15 min extraction (Figure 1B). The software triggered the valve switching. In  
171 position B the mobile phase from the HPLC pump was directed to the 5  $\mu$ L sample loop inserted  
172 on 10-port valve and thereby the enriched analytes was transferred into the HPLC column.

173

## 174 **2.4 HPLC equipment**

175 An Agilent 1100 series HPLC system (Agilent Technologies) was applied for the on-line  
176 LPME analysis as described in section 2.2. The LC separation was performed on a Zorbax  
177 Eclipse XDB-C18 column (Agilent Technologies) ( $4.6 \times 50$  mm,  $1.8 \mu$ m particle size). The flow  
178 rate was 0.8 mL/min. Using a short column packed with  $1.8 \mu$ m porous particles coupled with  
179 HPLC will shorten the analysis time without loss of the separation resolution compared to  
180 traditional 3-5  $\mu$ m based columns [28]. Acidified water (100 mM HCOOH) and ACN were used  
181 as the mobile phases A and B, respectively. The solvent gradient adopted was as follows: 5% B at  
182 0-2 min, 5-20% B at 2-4 min, 20% B at 4-10 min, 20-100% B at 10-12 min, followed by wash  
183 and equilibration. The analytes were detected using a UV detector at 282 nm. Baseline separation  
184 of the opium alkaloids was obtained in 10 min. The 10-port valve completely separated the low  
185 pressure of LPME-chip device from the HPLC system and the organic mobile phase never came  
186 in contact with the polymer chip. Acetonitrile in the mobile phase would otherwise have  
187 dissolved the PMMA and also modified the SLM used for the extraction.

188

## 189 **2.5 Extraction efficiency**

190 To determine the extraction efficiency of the model analytes, 50  $\mu$ L of diluted standard  
191 solution with 25 mM sodium octanoate was extracted as described above. The same standard  
192 solution (5  $\mu$ L unextracted) was also injected directly into the HPLC. Percentage recovery ( $R$  %)  
193 was calculated as follows:

$$194 \quad R = \frac{V_a \cdot C_{a \text{ final}}}{V_s \cdot C_{s \text{ initial}}}$$

195 Where  $V_a$  is the volume of acceptor solution (5  $\mu$ L) injected into the HPLC having the  
196 concentration  $C_{a \text{ final}}$ .  $V_s$  is the sample volume (50  $\mu$ L) injected from the autosampler into the  
197 LPME device having the concentration  $C_{s \text{ initial}}$ . Compared to the normal way of calculating the  
198 recovery for LPME, this equation also takes into account that not all the extracted compounds are



199 collected by the HPLC injection loop and the calculated recoveries reflect the amount of analytes  
200 collected and analysed by the HPLC.

201 The enrichment factor ( $EF$ ) for the analyte was calculated according to the following equation:

$$202 \quad EF = \frac{C_{a \text{ final}}}{C_{s \text{ initial}}}$$

203 Where  $C_{a \text{ final}}$  is the concentration of the enriched analyte solution injected into the HPLC and  
204  $C_{s \text{ initial}}$  is the concentration of analytes in the untreated sample. Since only 50  $\mu\text{L}$  of sample was  
205 injected into the LPME device and the acceptor volume injected into the HPLC was 5  $\mu\text{L}$ , the  
206 theoretical maximum enrichment factor was 10.

207 A standard curve using the LPME-chip–HPLC system was constructed for all analytes. For  
208 calculating the recovery, the standards prepared in 100 mM formic acid were injected directly  
209 into the 5  $\mu\text{L}$  loop on the 10-port valve by filling the standard solution directly into the loop with  
210 a microsyringe.

211

## 212 **3. Results and discussion**

### 213 **3.1 Principle of operation**

214 The primary purpose of coupling the LPME-chip directly to the HPLC was to provide on-line  
215 clean-up, enrichment, and analysis in micro-scale without time-consuming off-line sample  
216 preparation. All autosamplers that allow the control of an external valve can be used in  
217 combination with the LPME-chip. In this work the entire system was controlled from the Agilent  
218 Chemstation software. The basic setup and a photo of the automated LPME-chip-HPLC system  
219 are illustrated in Figure 1. Initially the HPLC 6-port valve was in the bypass position and the  
220 donor phase pumped directly through the chip. Meanwhile, the 10-port valve was in position A,  
221 where HPLC mobile phase was passed directly through the HPLC column. When the LPME  
222 process was initiated, the HPLC 6-port valve was triggered by the injection program and  
223 switched to the mainpass position (Table 1). In this mainpass position, the donor phase was  
224 directed through the injection needle and delivered 50  $\mu\text{L}$  sample solution directly towards the  
225 chip. The analytes were extracted across the SLM and into the acceptor phase. The acceptor  
226 phase was continuously pumped into a 5  $\mu\text{L}$  sample loop with a flow rate of 0.5  $\mu\text{L}/\text{min}$ . After 15  
227 minutes of LPME, the 10-port valve was programmed to switch to the position B, and the mobile  
228 phase was switched to pass by the sample loop. Thus, sample injection, transportation, membrane

229 extraction, and HPLC analysis were carried out coherently by the program. The next sample  
230 extraction was initiated after HPLC analysis, and during this 15 minutes extraction the HPLC  
231 column had time to equilibrate. After every third run in the sample sequence, 0.5  $\mu$ L 1-octanol  
232 was injected using the autosampler in order to regenerate the organic solvent of the membrane.  
233 This was important to maintain high repeatability, and relative standard deviations (RSD) were  
234 less than 10 % over 3 days' tests. A volume of 0.5  $\mu$ L 1-octanol was found appropriate based on  
235 experimental experience.

236

### 237 **3.2 Optimization of the extraction performance**

238 In a series of experiments, the chemical compositions of the sample, SLM, and acceptor were  
239 optimized with primary focus on extraction recovery. First, the five alkaloids were extracted with  
240 pure 1-octanol and NPOE as the SLM. The solvents were selected based on earlier experience  
241 from conventional LPME [29, 30]. The pH in the sample was adjusted to 11.0, and the acceptor  
242 was 10 mM HCl. With 1-octanol and NPOE, the extraction system was not efficient, and  
243 recoveries were below 3-4 % for all the model analytes. For morphine, codeine, thebaine, and  
244 noscapine, log P-values are below 2.0, and these analytes were too polar to be extracted  
245 effectively in the LPME-system. Papaverine is less polar (log P = 3.0), and the reason for the low  
246 recovery for this compound was not clear.

247 In a subsequent set of experiments, carrier-mediated LPME was tested as an alternative  
248 extraction principle. Based on earlier experience, sodium octanoate was selected as carrier and  
249 was added to the sample solution, and 1-octanol was used as SLM [29-31]. The concentration of  
250 sodium octanoate in the sample was 25 mM. Concentrations above this were not used to avoid  
251 potential precipitation of the carrier. The sample was adjusted to pH 7.0 to ensure that both the  
252 carrier (acidic) and the alkaloids (basic) were ionized. With 10 mM HCl as acceptor, recoveries  
253 ranged between 8 and 38 % (Table 2). Clearly, carrier-mediated LPME was more efficient, and  
254 analyte molecules ion-paired with octanoate ions and were transferred across the SLM. To further  
255 optimize the carried-mediated LPME, the concentration of HCl in the acceptor was increased  
256 from 10 to 50 mM, and recoveries improved correspondingly to the range 17 to 45 % (Table 2).  
257 These extraction recoveries were comparable with earlier findings from carrier-mediated LPME  
258 in a traditional set-up [29-32], and were therefore not optimized further in this work.

259

### 260 3.3. Performance of LPME-chip-HPLC device

261 Calibration curves were established in the concentration range of 0.01-10  $\mu\text{g}/\text{mL}$  for the five  
262 model alkaloids analysed with the LPME-HPLC system (Table 3). A linear relationship was  
263 obtained for all five opium alkaloids with  $R^2$ -values in the range 0.9959-0.9999. In addition,  
264 repeatability was tested based on five replicate experiments conducted with standard solutions of  
265 5  $\mu\text{g}/\text{mL}$ , and the RSD values were all below 11.0%.

266 In a final series of experiments, the LPME-chip was evaluated with human urine to test the  
267 compatibility of the system with a relevant biological matrix, and to indicate a potential  
268 application area for the future. In this experiment, the human urine spiked at the 2.5  $\mu\text{g}/\text{ml}$  level  
269 with the five opium alkaloids where extracted for 15 min. In Figure 2, direct HPLC analysis of  
270 the spiked urine sample (Figure 2a) was compared with LPME-chip processed urine sample  
271 (Figure 2b). With direct HPLC analysis, the signals of the five opium alkaloids co-eluted with the  
272 urine matrix. But as seen in Figure 2b, the LPME-chip-HPLC system provided excellent sample  
273 clean-up from the urine matrix. This illustrated a great potential for sample clean-up with the  
274 LPME-chip-HPLC system.

275 In order to examine the potential of applying the LPME-chip-HPLC for larger sample series,  
276 eighteen injections of spiked urine containing 2.5  $\mu\text{g}/\text{mL}$  of the alkaloids were introduced into the  
277 chip for extraction. The same membrane channel was used in 3 days to test repeatability and  
278 stability of measurements. As shown in Figure 3, the performance of the LPME-chip-HPLC  
279 system was stable and repeatable. The recovery of the five opium alkaloids in spiked urine  
280 sample were presented as follows: 12 % for morphine, 19 % for codeine, 36 % for thebaine, 28 %  
281 for papaverine and 22 % for noscapine with RSD values all below 10.0 %. The recoveries  
282 acquired here were slightly lower than from pure water samples as shown in Table 2. Minor  
283 matrix effect on the LPME extraction was probably attributed to the carrier-mediated extraction  
284 because of the formation of complexes of carrier and interfering ions in urine sample. The RSD  
285 values of peak areas for the 18 runs of spiked urine samples was 9.3% for morphine, 8.6% for  
286 codeine, 7.0% for thebaine, 8.0% for papaverine, and 9.9% for noscapine.

287

### 288 4. Conclusions

289 The present work has for the first time demonstrated coupling of a LPME-microchip device  
290 on-line to a HPLC instrument. This LPME-chip-HPLC system enabled automated injection,

291 extraction, separation, and detection of series of samples without any operator interaction. The  
292 LPME-chip effectively cleaned up samples and to some extent also pre-concentrated the analytes  
293 of interest. To avoid performance degradation of the supported liquid membrane, this was  
294 regularly regenerated as a part of the automated sequence by injection of a small volume of 1-  
295 octanol. The proof-of-principle of LPME-chip-HPLC system was evaluated with five opium  
296 alkaloids as model analytes, and demonstrated acceptable linearity and repeatability.

297

## 298 **Acknowledgements**

299 The Danish Council for Independent Research, Technology and Production Sciences (11-  
300 106647) is acknowledged for financial support.

301

302 **References**

- 303 [1] M.A.Z. Arruda, Trends in sample preparation, Nova Science Pub Incorporated, 2007.  
304 [2] P.L. Kole, G. Venkatesh, J. Kotecha, R. Sheshala, Biomed. Chromatogr., 25 (2011) 199-217.  
305 [3] J.Å. Jönsson, L. Mathiasson, TrAC, Trends Anal. Chem., 18 (1999) 318-325.  
306 [4] L. Chimuka, E. Cukrowska, M. Michel, B. Buszewski, TrAC, Trends Anal. Chem., 30 (2011) 1781-  
307 1792.  
308 [5] M.Á. Bello-López, M. Ramos-Payán, J.A. Ocaña-González, R. Fernández-Torres, M. Callejón-  
309 Mochón, Anal. Lett., 45 (2012) 804-830.  
310 [6] J.Å. Jönsson, L. Mathiasson, TrAC, Trends Anal. Chem., 18 (1999) 325-334.  
311 [7] A. Gjelstad, S. Pedersen-Bjergaard, Bioanalysis, 3 (2011) 787-797.  
312 [8] L.E.E. Eibak, A. Gjelstad, K.E. Rasmussen, S. Pedersen-Bjergaard, J Chromatogr A, 1217 (2010)  
313 5050-5056.  
314 [9] D.A. Lambropoulou, T.A. Albanis, J. Biochem. Bioph. Methods, 70 (2007) 195-228.  
315 [10] J.-F. Peng, J.-F. Liu, X.-L. Hu, G.-B. Jiang, J Chromatogr A, 1139 (2007) 165-170.  
316 [11] J. Raich-Montiu, K.A. Krogh, M. Granados, J.Å. Jönsson, B. Halling-Sørensen, J Chromatogr A,  
317 1187 (2008) 275-280.  
318 [12] M. Asensio-Ramos, L.M. Ravelo-Pérez, M.Á. González-Curbelo, J. Hernández-Borges, J  
319 Chromatogr A, 1218 (2011) 7415-7437.  
320 [13] M. Sandah, L. Mathiasson, J.A. Jonsson, J Chromatogr A, 975 (2002) 211-217.  
321 [14] L. Hou, G. Shen, H.K. Lee, J Chromatogr A, 985 (2003) 107-116.  
322 [15] M.D.R. Payan, B. Li, N.J. Petersen, H. Jensen, S.H. Hansen, S. Pedersen-Bjergaard, Anal. Chim.  
323 Acta, 785 (2013) 60-66.  
324 [16] A. Rosell, C. Palet, M. Valiente, Anal. Chim. Acta, 370 (1998) 141-149.  
325 [17] G. Audunsson, Anal Chem, 58 (1986) 2714-2723.  
326 [18] K. Hylton, S. Mitra, J Chromatogr A, 1152 (2007) 199-214.  
327 [19] A. Drapala, J.A. Jonsson, P. Wieczorek, Anal. Chim. Acta, 553 (2005) 9-14.  
328 [20] B. Lindegard, H. Bjork, J.A. Jonsson, L. Mathiasson, A.M. Olsson, Anal Chem, 66 (1994) 4490-4497.  
329 [21] Y. Shen, L. Mathiasson, Anal Chem, 70 (1998) 946-953.  
330 [22] S. Pálmarisdóttir, L. Mathiasson, J.Å. Jönsson, L.E. Edholm, Journal of Chromatography B:  
331 Biomedical Sciences and Applications, 688 (1997) 127-134.  
332 [23] M.D.R. Payan, H. Jensen, N.J. Petersen, S.H. Hansen, S. Pedersen-Bjergaard, Anal. Chim. Acta, 735  
333 (2012) 46-53.  
334 [24] N.J. Petersen, S.T. Foss, H. Jensen, S.H. Hansen, C. Skonberg, D. Snakenborg, J.P. Kutter, S.  
335 Pedersen-Bjergaard, Anal Chem, 83 (2011) 44-51.  
336 [25] N.J. Petersen, H. Jensen, S.H. Hansen, S.T. Foss, D. Snakenborg, S. Pedersen-Bjergaard, Microfluid  
337 Nanofluid, 9 (2010) 881-888.  
338 [26] X.Y. Wang, C. Saridara, S. Mitra, Anal. Chim. Acta, 543 (2005) 92-98.  
339 [27] N.J. Petersen, J.S. Pedersen, N.N. Poulsen, H. Jensen, C. Skonberg, S.H. Hansen, S. Pedersen-  
340 Bjergaard, Analyst, 137 (2012) 3321-3327.  
341 [28] B. Li, L.-W. Qi, X.-D. Wen, J. Cao, P. Li, J.-X. Zeng, H. Yang, J. Zhao, R. Hu, J Liq Chromatogr R  
342 T, 32 (2009) 2232-2245.  
343 [29] T.S. Ho, T.G. Halvorsen, S. Pedersen-Bjergaard, K.E. Rasmussen, J Chromatogr A, 998 (2003) 61-72.  
344 [30] T.S. Ho, J.L.E. Reubsæet, H.S. Anthonsen, S. Pedersen-Bjergaard, K.E. Rasmussen, J Chromatogr A,  
345 1072 (2005) 29-36.  
346 [31] T.S. Ho, S. Pedersen-Bjergaard, K.E. Rasmussen, J Chromatogr Sci, 44 (2006) 308-316.  
347 [32] A. Sarafray Yazdi, Z. Es'haghi, J Chromatogr A, 1094 (2005) 1-8.

348

349 **Table 1**

350 Inject program for LPME-chip-HPLC system using the Chemstation® software (Agilent  
351 technologies)

Step	Action*
1 <sup>a</sup>	Draw default sample from sample
2 <sup>b</sup>	Valve mainpass
3 <sup>c</sup>	Wait 15 min
4 <sup>d</sup>	Remote start request

352  
353 \* set action by using “Injector program” as injection mode  
354 <sup>a</sup> default inject sample volume set to 50 µL  
355 <sup>b</sup> switches the HPLC valve of the autosampler to connect the injected amount with the microsyringe carried donor  
356 phase (Fig. 1B)  
357 <sup>c</sup> set injection time needed for LPME,  
358 <sup>d</sup> stop extraction and trigger HPLC analysis (10 port valve switches to B position, whereby the extracted sample  
359 collected by the loop is injected onto the HPLC column)  
360

361 **Table 2**

362 Recovery obtained with carrier (sodium octanoate) mediated extraction and influence from the  
363 concentration of HCl in the acceptor phase.

Acceptor	Recovery % (RSD%, n=5)				
	morphine	codeine	thebaine	papaverine	noscapine
10 mM HCl	8 (7.2)	14 (6.6)	38 (7.9)	32 (5.2)	18 (8.8)
50 mM HCl	17 (6.9)	23 (6.2)	45 (9.9)	38 (5.0)	24 (10.8)

364

365 SLM: 1-octanol

366 sample: five opiates each at 5 µg/mL containing 25 mM sodium octanoate, pH 7.0, injection volume 50 µL;

367 donor phase: 25 mM phosphate buffer (pH 7.0), 5 µL/min;

368 acceptor phase:, 10 mM HCl, 0.5µL/min;

369 extraction time: 15 min.

370

371 **Table 3**

372 Analytical performance of LPME-chip-HPLC system

Analyte	Calibration curve <sup>a</sup>	Linear range ( $\mu\text{g/mL}$ )	$R^2$	LOD ( $\mu\text{g/mL}$ )
morphine	$y = 0.5005x + 0.174$	0.1-10	0.9998	0.021
codeine	$y = 0.8842x + 0.1847$	0.1-10	0.9999	0.021
thebaine	$y = 10.932x - 0.7379$	0.05-5	0.9969	0.001
papaverine	$y = 8.4735x + 0.785$	0.01-5	0.9991	0.001
noscapine	$y = 2.1787x - 0.2943$	0.1-10	0.9959	0.021

373

374 <sup>a</sup> y: peak area (mAU), x: sample concentration ( $\mu\text{g/mL}$ )375 SLM: 1-octanol, Injection volume: 50  $\mu\text{L}$ .376 Sample: 0.1-10  $\mu\text{g/mL}$  of the five opiates prepared in 25 mM sodium octanoate, pH 7.0.377 Donor phase: 5  $\mu\text{L/min}$ , 25 mM phosphate buffer pH 7.0,378 Acceptor phase: 0.5  $\mu\text{L/min}$ , 50 mM HCl; extraction time: 15 min.

379

380



381 **Figure caption**

382

383 **Figure 1** Photo (A) and schematic illustration (B) of automated LPME-chip-HPLC system. In  
384 Fig 1A, left panel (1) presented the overview of complete LPME-chip-HPLC device, and the  
385 right two panels showed the close-up view of the autosampler 6-port valve (2) as well as the chip  
386 system directly coupled to the external automated 10-port valve (3).

387

388 **Figure 2** On LPME-chip-HPLC for spiked human urine. a) Direct HPLC analysis of spiked urine  
389 sample. b) Spiked urine sample after 15 min extraction on the LPME-chip-HPLC. Urine sample:  
390 spiked with 5 opiates at 5  $\mu\text{g}/\text{mL}$ ; SLM liquid: 1-octanol; injection volume 50  $\mu\text{L}$ ; donor phase:  
391 5  $\mu\text{L}/\text{min}$ , 25 mM phosphate buffer (pH 7.0); acceptor phase: 0.5  $\mu\text{L}/\text{min}$ , 50 mM HCl.


392

393 **Figure 3** Repeatability tests of system with 18 runs were conducted in 3 days (6 runs per day)  
394 with the same channel cleaned with ethanol and dried after extraction every day. Urine sample:  
395 spiked with 5 opiates at 2.5  $\mu\text{g}/\text{mL}$ ; SLM liquid: 1-octanol; injection volume 50  $\mu\text{L}$ ; donor phase:  
396 5  $\mu\text{L}/\text{min}$ , 25 mM phosphate buffer (pH 7.0); acceptor phase: 0.5 $\mu\text{L}/\text{min}$ , 50 mM HCl; extraction  
397 time: 15 min.

398


399

A



400


B



401

402 **Figure 1**


403



404

405 **Figure 2**

406



407

408 **Figure 3**